At a forum in El Alamein, Egypt, Ghana's President John Dramani Mahama placed Africa's chronic dependence on imported medicines within a larger story of unrealized potential — arguing that the same billions flowing outward each year to foreign pharmaceutical suppliers could, with deliberate investment, flow inward as industrial growth, employment, and self-determination. His call was not merely economic but philosophical: that a continent of 2.5 billion people by mid-century cannot afford to treat its own health as someone else's product to sell back to it. The question he left hanging was whe
Mahama Urges Africa to Transform Healthcare Into High-Growth Economic Sector
Healthcare is not charity. It is an investable, high-growth business.
Mark
So Mahama is saying Africa should manufacture its own medicines instead of importing them. That's not new, is it? Why frame it as an economic opportunity rather than just a health need?
Mimi
Because the health need alone hasn't moved the money. Governments talk about health security all the time. But when you say "this is a 2.5 billion-person market with AfCFTA creating continental scale," you're speaking the language of investors. You're saying there's profit in solving the problem.
Luke
But does the infrastructure exist? He mentions the Africa CDC's pooled procurement working—African manufacturers got half the product lines. Half. That's not dominance. And he doesn't say how much capital is actually available, or what the barriers to entry are for a new pharmaceutical manufacturer.
Mimi
Fair. He's making the case for why it should happen, not proving it will. But the pooled procurement example is real—it shows the mechanism can work at scale.
Mark
What about the donor dependence angle? He says traditional donor support is declining. Is that a crisis or an opportunity?
Mimi
Both. If donors are pulling back, countries have to find other ways to fund health. That's the pressure. But it also means they can't wait for charity anymore—they have to build systems that work on their own revenue.
Luke
The Ghana initiatives—MahamaCares, the expanded insurance scheme—those are financing mechanisms, not manufacturing capacity. You can have all the money in the world and still not be able to make vaccines if you don't have the technical expertise, the regulatory framework, the supply chains for raw materials. He's conflating healthcare financing with pharmaceutical manufacturing.
Mimi
He's not conflating them—he's saying they're both necessary. You need the demand side (financing) and the supply side (manufacturing). Ghana is trying to build both.
Mark
So what's the actual risk here? What could go wrong?
Luke
Overcapacity. If multiple African countries all try to build pharmaceutical manufacturing at once, you could end up with underutilized plants and wasted capital. And there's the question of quality and regulatory standards. Africa doesn't have a unified pharmaceutical regulator. Who ensures the medicines are safe?
Mimi
That's where health sovereignty comes in—building the regulatory capacity alongside the manufacturing. It's not just about making pills; it's about making them safely and consistently.
Mark
And the timeline? When does this actually happen?
Luke
He doesn't say. The population projection is 2050. The AfCFTA is already in place. But actual manufacturing facilities take years to build and billions to finance. This is a long game.
Il Polso
- Africa sends tens of billions of dollars abroad annually for medicines and vaccines it has the capacity — but not yet the infrastructure — to produce at home, leaving its health systems exposed every time global supply chains fracture.
- Mahama reframed the crisis as an investment thesis: a continent importing over 70% of its pharmaceuticals and 99% of its vaccines is not a charity case but an undercapitalized market waiting for domestic producers to step in.
- The AfCFTA and pooled procurement models like the Africa CDC's maternal health initiative offer a concrete path forward — giving manufacturers continental-scale demand and price stability that could justify the capital commitments required.
- Ghana is already testing this logic through MahamaCares, expanded national health insurance, and a push toward domestic pharmaceutical manufacturing, treating health sovereignty as a policy goal rather than an aspiration.
- The trajectory is promising but unresolved — the infrastructure, financing, and political will are beginning to align, yet the gap between vision and execution remains the defining challenge for African governments and investors alike.
At a forum in El Alamein, Egypt, Ghana's President John Dramani Mahama placed Africa's chronic dependence on imported medicines within a larger story of unrealized potential — arguing that the same billions flowing outward each year to foreign pharmaceutical suppliers could, with deliberate investment, flow inward as industrial growth, employment, and self-determination. His call was not merely economic but philosophical: that a continent of 2.5 billion people by mid-century cannot afford to treat its own health as someone else's product to sell back to it. The question he left hanging was whether ambition and capital would finally arrive together.
At the inaugural Alamein Africa Forum in El Alamein, Egypt, Ghana's President John Dramani Mahama made a case that was as much economic as it was moral: Africa is hemorrhaging tens of billions of dollars annually on imported pharmaceuticals and vaccines it could be manufacturing itself. More than seventy percent of the continent's medicines and virtually all of its vaccines come from abroad — a dependency that drains wealth and leaves health systems dangerously exposed when global supply chains falter.
Mahama urged African governments, financial institutions, and private investors to stop categorizing healthcare as a social expenditure and begin treating it as a high-growth sector capable of driving industrialization and building resilience. The arithmetic, he argued, is compelling. With Africa's population projected to reach 2.5 billion by 2050, the demand for essential medicines, chronic disease treatments, and biologics will only intensify — and a continent producing for itself at that scale represents a market of genuine consequence.
The African Continental Free Trade Area amplifies the opportunity further, allowing domestic manufacturers to serve the entire continent rather than individual national markets. Pooled procurement mechanisms, like the Africa CDC's existing initiative for maternal and child health products, demonstrate the model's viability — generating meaningful price reductions while enabling African manufacturers to capture half of the relevant product lines.
Ghana is already attempting to live out this vision. The country is expanding domestic pharmaceutical manufacturing and anchoring its health financing strategy around three initiatives: a strengthened National Health Insurance Scheme, a Free Primary Health Care Programme, and the Ghana Medical Trust Fund, known as MahamaCares. Together, they represent a deliberate effort to build a health system capable of sustaining itself without perpetual dependence on donor support.
What Mahama described, at its core, is health sovereignty — the capacity to finance, regulate, manufacture, and supply essential health services from within. Africa's current import dependence, in his framing, is not a permanent condition but a correctable market failure. Whether African governments and investors will move decisively enough to correct it remains the open question.
At a forum in El Alamein, Egypt, Ghana's President John Dramani Mahama made a straightforward economic argument: African nations are spending tens of billions of dollars every year to import medicines and vaccines they could be making themselves. The continent buys more than seventy percent of its pharmaceuticals from abroad and nearly all of its vaccines—ninety-nine percent—from international suppliers. That money leaves African economies and leaves them vulnerable when global supply chains break. But Mahama saw something else in those numbers: opportunity.
Speaking at the inaugural Alamein Africa Forum's plenary session on investing in health, manufacturing, and regional value chains, Mahama urged African governments, financial institutions, and private investors to stop treating healthcare as a social cost and start treating it as a sector capable of driving industrialization, creating jobs, and building economic resilience. The shift in framing matters. Healthcare, he argued, is not charity. It is an investable, high-growth business.
The math supports the case. Africa's population is projected to reach about 2.5 billion by 2050. That means growing demand for essential medicines, treatments for chronic diseases, vaccines, and biologics. A continent of that size, producing for itself, represents a market of genuine scale. Add the African Continental Free Trade Area—the AfCFTA—and the picture expands further. Local manufacturers would no longer be confined to domestic markets. They could produce for the entire continent. Pooled procurement mechanisms, like the one the Africa CDC has already established for maternal and child health products, could create predictable demand that gives manufacturers the confidence to invest and expand. That same CDC initiative, Mahama noted, generated substantial price reductions while enabling African manufacturers to capture half of the product lines.
Ghana itself is already moving in this direction. The country is working to shift from being primarily a consumer of health products to a producer. The strategy includes strengthening domestic pharmaceutical manufacturing, expanding healthcare financing, and reducing reliance on donor-funded vaccine programs. Three initiatives anchor this effort: an expansion of the National Health Insurance Scheme, the Free Primary Health Care Programme, and the Ghana Medical Trust Fund, known as MahamaCares. Together, they represent an attempt to build a health system that can sustain itself rather than depend on external support.
What Mahama was describing is health sovereignty—the capacity of African countries to finance their own essential health services, regulate their own products, manufacture their own medicines, and maintain resilient supply chains without waiting for international goodwill or global markets to cooperate. It is a vision that treats the continent's current import dependence not as a permanent condition but as a market failure waiting to be corrected by capital and ambition. The question now is whether African governments and investors will act on it.
Citazioni salienti
The continent's quest for health sovereignty presents a significant investment opportunity for African businesses and financial institutions.— President John Dramani Mahama
Achieving health sovereignty requires countries to develop the capacity to finance essential health services, regulate products effectively, manufacture essential medicines and establish resilient supply chains.— President John Dramani Mahama
Vuoi la storia completa?
Leggi l'originale su allAfrica.com ↗